Morphing cholinesterase inhibitor amiridine into multipotent drugs for the treatment of Alzheimer's disease
The search for novel drugs to address the medical needs of Alzheimer's disease (AD) is an ongoing process relying on the discovery of disease-modifying agents. Given the complexity of the disease, such an aim can be pursued by developing so-called multi-target directed ligands (MTDLs) that will...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-04-01
|
| Series: | Biomedicine & Pharmacotherapy |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S075333222400283X |
| _version_ | 1797248409923485696 |
|---|---|
| author | Eva Mezeiova Lukas Prchal Martina Hrabinova Lubica Muckova Lenka Pulkrabkova Ondrej Soukup Anna Misiachna Jiri Janousek Jakub Fibigar Tomas Kucera Martin Horak Galina F. Makhaeva Jan Korabecny |
| author_facet | Eva Mezeiova Lukas Prchal Martina Hrabinova Lubica Muckova Lenka Pulkrabkova Ondrej Soukup Anna Misiachna Jiri Janousek Jakub Fibigar Tomas Kucera Martin Horak Galina F. Makhaeva Jan Korabecny |
| author_sort | Eva Mezeiova |
| collection | DOAJ |
| description | The search for novel drugs to address the medical needs of Alzheimer's disease (AD) is an ongoing process relying on the discovery of disease-modifying agents. Given the complexity of the disease, such an aim can be pursued by developing so-called multi-target directed ligands (MTDLs) that will impact the disease pathophysiology more comprehensively. Herewith, we contemplated the therapeutic efficacy of an amiridine drug acting as a cholinesterase inhibitor by converting it into a novel class of novel MTDLs. Applying the linking approach, we have paired amiridine as a core building block with memantine/adamantylamine, trolox, and substituted benzothiazole moieties to generate novel MTDLs endowed with additional properties like N-methyl-d-aspartate (NMDA) receptor affinity, antioxidant capacity, and anti-amyloid properties, respectively. The top-ranked amiridine-based compound 5d was also inspected by in silico to reveal the butyrylcholinesterase binding differences with its close structural analogue 5b. Our study provides insight into the discovery of novel amiridine-based drugs by broadening their target-engaged profile from cholinesterase inhibitors towards MTDLs with potential implications in AD therapy. |
| first_indexed | 2024-04-24T20:14:08Z |
| format | Article |
| id | doaj.art-567776fbc85843eba2bb66f04d9469c0 |
| institution | Directory Open Access Journal |
| issn | 0753-3322 |
| language | English |
| last_indexed | 2024-04-24T20:14:08Z |
| publishDate | 2024-04-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Biomedicine & Pharmacotherapy |
| spelling | doaj.art-567776fbc85843eba2bb66f04d9469c02024-03-23T06:23:01ZengElsevierBiomedicine & Pharmacotherapy0753-33222024-04-01173116399Morphing cholinesterase inhibitor amiridine into multipotent drugs for the treatment of Alzheimer's diseaseEva Mezeiova0Lukas Prchal1Martina Hrabinova2Lubica Muckova3Lenka Pulkrabkova4Ondrej Soukup5Anna Misiachna6Jiri Janousek7Jakub Fibigar8Tomas Kucera9Martin Horak10Galina F. Makhaeva11Jan Korabecny12University Hospital Hradec Kralove, Biomedical Research Centre, Sokolska 581, Hradec Kralove 500 05, Czech RepublicUniversity Hospital Hradec Kralove, Biomedical Research Centre, Sokolska 581, Hradec Kralove 500 05, Czech RepublicUniversity Hospital Hradec Kralove, Biomedical Research Centre, Sokolska 581, Hradec Kralove 500 05, Czech Republic; University of Defence, Military Faculty of Medicine, Department of Toxicology and Military Pharmacy, Trebesska 1575, Hradec Kralove 500 01, Czech RepublicUniversity Hospital Hradec Kralove, Biomedical Research Centre, Sokolska 581, Hradec Kralove 500 05, Czech Republic; University of Defence, Military Faculty of Medicine, Department of Toxicology and Military Pharmacy, Trebesska 1575, Hradec Kralove 500 01, Czech RepublicUniversity Hospital Hradec Kralove, Biomedical Research Centre, Sokolska 581, Hradec Kralove 500 05, Czech Republic; University of Defence, Military Faculty of Medicine, Department of Toxicology and Military Pharmacy, Trebesska 1575, Hradec Kralove 500 01, Czech RepublicUniversity Hospital Hradec Kralove, Biomedical Research Centre, Sokolska 581, Hradec Kralove 500 05, Czech Republic; University of Defence, Military Faculty of Medicine, Department of Toxicology and Military Pharmacy, Trebesska 1575, Hradec Kralove 500 01, Czech RepublicInstitute of Experimental Medicine of the Czech Academy of Sciences, Department of Neurochemistry, Videnska 1083, Prague 14220, Czech Republic; Charles University in Prague, Department of Physiology, Faculty of Science, Albertov 6, Prague 2, Czech RepublicUniversity Hospital Hradec Kralove, Biomedical Research Centre, Sokolska 581, Hradec Kralove 500 05, Czech RepublicUniversity of Defence, Military Faculty of Medicine, Department of Toxicology and Military Pharmacy, Trebesska 1575, Hradec Kralove 500 01, Czech RepublicUniversity of Defence, Military Faculty of Medicine, Department of Toxicology and Military Pharmacy, Trebesska 1575, Hradec Kralove 500 01, Czech RepublicInstitute of Experimental Medicine of the Czech Academy of Sciences, Department of Neurochemistry, Videnska 1083, Prague 14220, Czech Republic; Corresponding authors.Russian Academy of Sciences, Institute of Physiologically Active Compounds at Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Severny proezd 1, Chernogolovka 142432, Russia; Corresponding authors.University Hospital Hradec Kralove, Biomedical Research Centre, Sokolska 581, Hradec Kralove 500 05, Czech Republic; University of Defence, Military Faculty of Medicine, Department of Toxicology and Military Pharmacy, Trebesska 1575, Hradec Kralove 500 01, Czech Republic; Corresponding author at: University Hospital Hradec Kralove, Biomedical Research Centre, Sokolska 581, Hradec Kralove 500 05, Czech Republic.The search for novel drugs to address the medical needs of Alzheimer's disease (AD) is an ongoing process relying on the discovery of disease-modifying agents. Given the complexity of the disease, such an aim can be pursued by developing so-called multi-target directed ligands (MTDLs) that will impact the disease pathophysiology more comprehensively. Herewith, we contemplated the therapeutic efficacy of an amiridine drug acting as a cholinesterase inhibitor by converting it into a novel class of novel MTDLs. Applying the linking approach, we have paired amiridine as a core building block with memantine/adamantylamine, trolox, and substituted benzothiazole moieties to generate novel MTDLs endowed with additional properties like N-methyl-d-aspartate (NMDA) receptor affinity, antioxidant capacity, and anti-amyloid properties, respectively. The top-ranked amiridine-based compound 5d was also inspected by in silico to reveal the butyrylcholinesterase binding differences with its close structural analogue 5b. Our study provides insight into the discovery of novel amiridine-based drugs by broadening their target-engaged profile from cholinesterase inhibitors towards MTDLs with potential implications in AD therapy.http://www.sciencedirect.com/science/article/pii/S075333222400283XAmiridineAcetylcholinesteraseAntioxidant capacityButyrylcholinesteraseMulti-target directed ligandsNMDA receptors |
| spellingShingle | Eva Mezeiova Lukas Prchal Martina Hrabinova Lubica Muckova Lenka Pulkrabkova Ondrej Soukup Anna Misiachna Jiri Janousek Jakub Fibigar Tomas Kucera Martin Horak Galina F. Makhaeva Jan Korabecny Morphing cholinesterase inhibitor amiridine into multipotent drugs for the treatment of Alzheimer's disease Biomedicine & Pharmacotherapy Amiridine Acetylcholinesterase Antioxidant capacity Butyrylcholinesterase Multi-target directed ligands NMDA receptors |
| title | Morphing cholinesterase inhibitor amiridine into multipotent drugs for the treatment of Alzheimer's disease |
| title_full | Morphing cholinesterase inhibitor amiridine into multipotent drugs for the treatment of Alzheimer's disease |
| title_fullStr | Morphing cholinesterase inhibitor amiridine into multipotent drugs for the treatment of Alzheimer's disease |
| title_full_unstemmed | Morphing cholinesterase inhibitor amiridine into multipotent drugs for the treatment of Alzheimer's disease |
| title_short | Morphing cholinesterase inhibitor amiridine into multipotent drugs for the treatment of Alzheimer's disease |
| title_sort | morphing cholinesterase inhibitor amiridine into multipotent drugs for the treatment of alzheimer s disease |
| topic | Amiridine Acetylcholinesterase Antioxidant capacity Butyrylcholinesterase Multi-target directed ligands NMDA receptors |
| url | http://www.sciencedirect.com/science/article/pii/S075333222400283X |
| work_keys_str_mv | AT evamezeiova morphingcholinesteraseinhibitoramiridineintomultipotentdrugsforthetreatmentofalzheimersdisease AT lukasprchal morphingcholinesteraseinhibitoramiridineintomultipotentdrugsforthetreatmentofalzheimersdisease AT martinahrabinova morphingcholinesteraseinhibitoramiridineintomultipotentdrugsforthetreatmentofalzheimersdisease AT lubicamuckova morphingcholinesteraseinhibitoramiridineintomultipotentdrugsforthetreatmentofalzheimersdisease AT lenkapulkrabkova morphingcholinesteraseinhibitoramiridineintomultipotentdrugsforthetreatmentofalzheimersdisease AT ondrejsoukup morphingcholinesteraseinhibitoramiridineintomultipotentdrugsforthetreatmentofalzheimersdisease AT annamisiachna morphingcholinesteraseinhibitoramiridineintomultipotentdrugsforthetreatmentofalzheimersdisease AT jirijanousek morphingcholinesteraseinhibitoramiridineintomultipotentdrugsforthetreatmentofalzheimersdisease AT jakubfibigar morphingcholinesteraseinhibitoramiridineintomultipotentdrugsforthetreatmentofalzheimersdisease AT tomaskucera morphingcholinesteraseinhibitoramiridineintomultipotentdrugsforthetreatmentofalzheimersdisease AT martinhorak morphingcholinesteraseinhibitoramiridineintomultipotentdrugsforthetreatmentofalzheimersdisease AT galinafmakhaeva morphingcholinesteraseinhibitoramiridineintomultipotentdrugsforthetreatmentofalzheimersdisease AT jankorabecny morphingcholinesteraseinhibitoramiridineintomultipotentdrugsforthetreatmentofalzheimersdisease |